今日,CDE官网显示,中山康方生物医药有限公司开发的AK139注射液又获批2项适应症临床:慢性鼻窦炎伴鼻息肉、中重度特应性皮炎。该药最早于2025年4月获CDE临床试验批准,截止至目前,已获批开展5项适应症临床。(图片来源:CDE)关注新药社,每日为你介绍全球新药信息AK139注射液是康方生物自主研发的1类创新生物药,为全球首创人白介素4受体(IL-4Rα)/致瘤性抑制蛋白2(ST2)双特异性重组...
Source Link今日,CDE官网显示,中山康方生物医药有限公司开发的AK139注射液又获批2项适应症临床:慢性鼻窦炎伴鼻息肉、中重度特应性皮炎。该药最早于2025年4月获CDE临床试验批准,截止至目前,已获批开展5项适应症临床。(图片来源:CDE)关注新药社,每日为你介绍全球新药信息AK139注射液是康方生物自主研发的1类创新生物药,为全球首创人白介素4受体(IL-4Rα)/致瘤性抑制蛋白2(ST2)双特异性重组...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.